Epidemiology of Severe Myoclonic Epilepsy of Infancy
The DOI matches its Crossref record.
Abstract
Summary: Severe myoclonic epilepsy of infancy (SMEI) is a newly recognized epileptic syndrome. It is characterized by multiple febrile seizures, often prolonged, subsequent development of uncontrollable mixed‐myoclonic seizures, and, eventually, psychomotor retardation. Drugs for myoclonic epilepsy–valproate (VPA), the suximides, and the benzodiazepines–have been shown to be useful in SMEI. Among children with seizures in the National Institute of Neurological and Communicative Disorders and Stroke Collaborative Perinatal Project (NCPP), one individual with SMEI was identified. This finding from the NCPP suggests that the incidence of SMEI is ∽1 in 40,000 children. Such an incidence is supported by observations at the Texas Tech University Health Sciences Center. RÉSUMÉ: L'épilepsie myoclonique sévère du nourrisson (EMSN) est un syndrome épileptique d'individualisation récente. II est caractérisé par des crises fébriles multiples, souvent prolongées, avec installation secondaire de crises à composante myoclonique difficiles à contrôler et d'un retard psychomoteur. Les médicaments de l'épilepsie myoclonique (valproate, succimides, benzodiazépines) sont utiles dans le traitement de l'EMSN. Parmi les enfants ayant présenté des crises, pris en charge dans le projet collaboratif péri‐natal de l'Institut National des Maladies Neurologiques et de la Communication et des Maladies Vasculaires (NCPP), les auteurs ont identifié un patient présentant une EMSN. Cette constatation suggère que l'incidence de l'EMSN est d' environ 1 pour 40,000 enfants. Une telle incidence est confirmée par les observations effectuées au Centre Médical de l'Université Technologique du Texas. RESUMEN: La epilepsia mioclónica severe de la infancia (SMEI) es un síndrome reconocido recientemente. Se caracteriza por múltiples ataques febriles, frecuentemente prolongados. desarrollo subsiguiente de ataques combinados de myoclonias que son incontrolables y, eventualmente, de retraso pskomotor. Las medicación para la epilepsia mioclónica: el valproate Us suximidas y las benzodiazepinas, han demostrado ser eficaces en el SMEI. Entre los niños con ataques que se incluyeron en el proyecto del Instituto Nacional de Trastornos Neurológicos y de U Comunicación y en el Estudio Colaborativo del Institute Perinatal (NCPP) se identificó un individuo con SMEI. Este hallazgo en el NCPP sugiere que la incidencia de la SMEI es aproximadamente 1 en 40,000. Esta incidencia es semejante a la observada en el Centra de Ciencias de la Salud de la Universidad Technológica de Texas. ZUSAMMENFASSUNG: Die sebwere frühkindliche myoklonische Epilepsie (SME) ist ein neuerkanntes epileptisches Syndrom. Es wird charakterisiert durch rezidivierende, oft prolongierte Fieberkrärnpfe mit nachfolgend sich entwickelnden gemischten m yoklomschen Anfällen und möglicher psychomotorischer Retardierung. Für die Behandlung erweisen sich Medikamente für myoklonische Epilepsien als wirksam wie Valproat, Suximide, Benzodiazepine, Unter den Kindern mit Anfällen fand sich eines mit einer SME im National Institute of Neurological and Communicative Disorders und in dem Stroke collaborative Perinatal Project (NCPP). Dieses Ergebnis des NCPP läβt eine annähernde Schätzung der Inzidenz der SME mit 1/40,000 zu. Diese Inzidenz wird durch die Beobachtungen an der Texas Tech. University Health Sciences Center bestätigt.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The core Dravet syndrome phenotype
Dravet, C. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.02994.x · Cited by 627
The genetic landscape of the epileptic encephalopathies of infancy and childhood
McTague, A., Howell, K. B., Cross, J. H., Kurian, M. A., & Scheffer, I. E. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00250-1 · Cited by 604
Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome
Brunklaus, A., Ellis, R., Reavey, E., Forbes, G. H., & Zuberi, S. M. (2012) · Brain · doi:10.1093/brain/aws151 · Cited by 366
“Previous American and French findings from smaller cohorts had approximated similar incidence figures ranging from 1:20 000 to 1:40 000 making Dravet syndrome a rare disease (Hurst, 1990; Yakoub et al., 1992).”
Wolff, M., Cassé‐Perrot, C., & Dravet, C. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00688.x · Cited by 308
Incidence of Dravet Syndrome in a US Population
Wu, Y. W., Sullivan, J., McDaniel, S. S., Meisler, M. H., Walsh, E. M., Li, S. X., & Kuzniewicz, M. W. (2015) · Pediatrics · doi:10.1542/peds.2015-1807 · Cited by 248
Metadata
- Authors
- Hurst, D. L.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 1990-08
- Volume
- 31
- Issue
- 4
- Pages
- 397-400
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W1991286554
- Cited by
- 124
- References
- 0
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epidemiology of Severe Myoclonic Epilepsy of Infancy. https://app.cochat.ai/papers/10.1111/j.1528-1157.1990.tb05494.x
- The paper
- Hurst, D. L. (1990). Epidemiology of Severe Myoclonic Epilepsy of Infancy. Epilepsia. https://doi.org/10.1111/j.1528-1157.1990.tb05494.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.